Nucleos(t)ide antiviral agents for preventing mother-to-child transmission of hepatitis B virus: an interpretation of relevant international guidelines.
10.3760/cma.j.issn.1007-3418.2016.02.016
- VernacularTitle:核苷(酸)类抗病毒药物用于乙型肝炎母婴阻断-国际相关指南解读
- Author:
Jie LI
1
Author Information
1. Department of Microbiology and Infectious Diseases Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing100191, China.
- Publication Type:Journal Article
- MeSH:
Antiviral Agents;
therapeutic use;
DNA, Viral;
blood;
Female;
Hepatitis B;
drug therapy;
prevention & control;
Humans;
Infant, Newborn;
Infectious Disease Transmission, Vertical;
prevention & control;
Nucleosides;
therapeutic use;
Nucleotides;
therapeutic use;
Practice Guidelines as Topic;
Pregnancy;
Pregnancy Complications, Infectious;
virology;
Viral Load
- From:
Chinese Journal of Hepatology
2016;24(2):143-146
- CountryChina
- Language:Chinese
-
Abstract:
A high maternal viral load is the most important factor affecting immunoprophylaxis against mother-infant transmission of HBV. The application of antiviral drugs in pregnant women with a high serum HBV DNA level (>10(6)~10(7) IU/ml) during the second and third trimesters can reduce the prenatal serum HBV DNA level and significantly increase the success rate of blocking mother-infant transmission in neonates. This article interprets the contents related to antiviral therapy for pregnant women carrying HBV with the purpose of blocking mother-infant transmission of HBV in the guidelines published by Asian Pacific Association for the Study of the Liver, European Association for the Study of the Liver, National Institute for Health and Care Excellence, Korean Association for the Study of the Liver, and World Health Organization.
